Pasithea Therapeutics Corp. (KTTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 20, 2025, covers a series of corporate announcements made between November 20 and November 25, 2025. Pasithea Therapeutics Corp., an emerging growth company, reported significant clinical and funding milestones for its lead candidate, PAS-004, a first-in-human therapy targeting MAPK pathway alterations in advanced solid tumors and neurofibromatosis type 1 (NF1).
Key Financial Metrics
The filing does not provide specific financial statements, revenue, profit, cash flow, or debt metrics. The only financial figure disclosed is a grant award of approximately $1 million from the ALS Association for a clinical trial studying PAS-004 in ALS patients.
Material Changes and Clinical Updates
The report details four distinct updates regarding PAS-004:
- Interim Phase 1 Efficacy (Nov 20): In 21 efficacy-evaluable patients with advanced solid tumors, the Drug Control Rate (DCR) was 42.8% (9 of 21). Among patients with BRAF-mutated tumors, the DCR was 71.4% (5 of 7). One patient with BRAF V600E melanoma achieved an unconfirmed partial response with a -31.9% tumor reduction after >11 months on trial.
- Safety Profile (Nov 20): Among 27 dosed patients, PAS-004 was well-tolerated with no dose-limiting toxicities (DLTs) or discontinuations. All treatment-related adverse events were Grade 1 or 2, including nausea (18.5%), vomiting (14.8%), and rash (7.4%). No ocular or cardiovascular toxicities were observed.
- Tablet Formulation PK (Nov 21): In the NF1 trial, the tablet formulation demonstrated linear PK and dose-proportionality. Dose-normalized exposures were approximately 3-fold higher than the capsule formulation, with the 8mg tablet showing higher AUC and Cmax than the 22mg capsule.
- Cohort 7 Escalation (Nov 24): The 37mg capsule cohort showed no DLTs and zero treatment-related adverse events during the DLT period. Pharmacodynamics data indicated 80% inhibition of pERK near Cmax and >60% inhibition at Cmin. The Safety Review Committee recommended proceeding to Cohort 8 (45mg capsule).
Guidance, Outlook, and Risks
Management indicated positive momentum with the recommendation to escalate dosing to 45mg and the successful demonstration of a superior tablet formulation. The company received a Hoffman ALS Clinical Trial Award to study PAS-004 in ALS. The filing includes standard forward-looking statement disclaimers, noting that future clinical results may differ from current observations, may not reach statistical significance, and are subject to regulatory approval risks.
Investor Verification Checklist
- Verify the specific patient demographics and prior treatment history for the 21 efficacy-evaluable patients to assess the strength of the 42.8% DCR.
- Confirm the timeline for the initiation of Cohort 8 (45mg capsule) and the enrollment status of the NF1 tablet formulation study.
- Review the terms of the $1 million ALS Association grant to understand the scope and duration of the proposed ALS trial.
- Monitor upcoming filings for the full safety data of the 37mg cohort and the results of the 45mg escalation.
- Check the company's cash runway in the most recent 10-Q or 10-K, as this 8-K does not disclose liquidity or burn rate.